JP2016530233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530233A5 JP2016530233A5 JP2016524319A JP2016524319A JP2016530233A5 JP 2016530233 A5 JP2016530233 A5 JP 2016530233A5 JP 2016524319 A JP2016524319 A JP 2016524319A JP 2016524319 A JP2016524319 A JP 2016524319A JP 2016530233 A5 JP2016530233 A5 JP 2016530233A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- tumor
- bacterial cell
- nucleic acid
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361842749P | 2013-07-03 | 2013-07-03 | |
| US61/842,749 | 2013-07-03 | ||
| PCT/US2014/045086 WO2015002969A1 (en) | 2013-07-03 | 2014-07-01 | Anticancer combinations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087445A Division JP2019167346A (ja) | 2013-07-03 | 2019-05-07 | 抗癌組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530233A JP2016530233A (ja) | 2016-09-29 |
| JP2016530233A5 true JP2016530233A5 (https=) | 2017-08-03 |
| JP6896420B2 JP6896420B2 (ja) | 2021-06-30 |
Family
ID=52144163
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524319A Active JP6896420B2 (ja) | 2013-07-03 | 2014-07-01 | 抗癌組成物 |
| JP2019087445A Pending JP2019167346A (ja) | 2013-07-03 | 2019-05-07 | 抗癌組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087445A Pending JP2019167346A (ja) | 2013-07-03 | 2019-05-07 | 抗癌組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11141492B2 (https=) |
| EP (1) | EP3016716B1 (https=) |
| JP (2) | JP6896420B2 (https=) |
| KR (1) | KR20160027971A (https=) |
| CN (1) | CN105407974A (https=) |
| AU (1) | AU2014284396A1 (https=) |
| BR (1) | BR112015033053A2 (https=) |
| CA (1) | CA2917102A1 (https=) |
| IL (1) | IL243323A0 (https=) |
| WO (1) | WO2015002969A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201519734D0 (en) | 2015-11-09 | 2015-12-23 | Univ Swansea | Cancer therapy |
| EP3516397A1 (en) * | 2016-09-23 | 2019-07-31 | Ventana Medical Systems, Inc. | Methods and systems for scoring extracellular matrix biomarkers in tumor samples |
| EP3652318A1 (en) | 2017-07-11 | 2020-05-20 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| JP7340591B2 (ja) | 2018-07-11 | 2023-09-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
| US11242528B2 (en) | 2018-08-28 | 2022-02-08 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| JP2022524951A (ja) | 2019-02-27 | 2022-05-11 | アクティム・セラピューティクス・インコーポレイテッド | 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌 |
| US20220193149A1 (en) * | 2019-05-16 | 2022-06-23 | City Of Hope | Compositions and methods for targeting tumor-associated extracellular matrix components to improve drug delivery |
| JP2023501539A (ja) | 2019-11-12 | 2023-01-18 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用 |
| IL300447A (en) | 2020-08-12 | 2023-04-01 | Actym Therapeutics Inc | Bacteria-based ingredients that stimulate the immune system, treatments and platforms for delivering RNA |
| CN113769063B (zh) * | 2021-09-30 | 2024-01-19 | 浙江大学 | 一种多肽ptpr在制备肿瘤免疫治疗药物中的应用 |
| KR102680316B1 (ko) * | 2021-11-01 | 2024-07-01 | 오토텔릭바이오 주식회사 | 안티센스 올리고뉴클레오타이드 |
| WO2023086796A2 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| CN115838720A (zh) * | 2022-07-28 | 2023-03-24 | 吉林启众生物科技有限公司 | 一种携带shSTAT3/shPD-L1重组质粒的减毒沙门氏菌载体及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR013269A1 (es) | 1997-08-04 | 2000-12-13 | Scras | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US20050112141A1 (en) * | 2000-08-30 | 2005-05-26 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| CA2433680A1 (en) | 2000-12-28 | 2002-08-01 | Gregory M Arndt | Double-stranded rna-mediated gene suppression |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| WO2005018332A1 (en) * | 2003-08-13 | 2005-03-03 | The General Hospital Corporation | Modified microorganisms for anti-cancer therapy |
| WO2007095387A2 (en) | 2006-02-17 | 2007-08-23 | Dharmacon, Inc. | Compositions and methods for inhibiting gene silencing by rna interference |
| CN1974759B (zh) * | 2006-07-26 | 2010-06-09 | 吉林大学 | 运载重组质粒的减毒沙门氏菌及其在抗肿瘤中的应用 |
| AU2007299705B2 (en) | 2006-09-22 | 2012-09-06 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference |
| US20100239546A1 (en) * | 2007-06-15 | 2010-09-23 | Beth Israel Deaconess Medical Center | Bacterial mediated tnf alpha gene silencing |
| KR20130116386A (ko) * | 2008-04-14 | 2013-10-23 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
| WO2012149364A1 (en) * | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
-
2014
- 2014-07-01 WO PCT/US2014/045086 patent/WO2015002969A1/en not_active Ceased
- 2014-07-01 BR BR112015033053A patent/BR112015033053A2/pt not_active Application Discontinuation
- 2014-07-01 KR KR1020167001786A patent/KR20160027971A/ko not_active Withdrawn
- 2014-07-01 CN CN201480041314.4A patent/CN105407974A/zh active Pending
- 2014-07-01 CA CA2917102A patent/CA2917102A1/en not_active Abandoned
- 2014-07-01 JP JP2016524319A patent/JP6896420B2/ja active Active
- 2014-07-01 EP EP14819900.3A patent/EP3016716B1/en active Active
- 2014-07-01 AU AU2014284396A patent/AU2014284396A1/en not_active Abandoned
-
2015
- 2015-12-22 US US14/978,590 patent/US11141492B2/en active Active
- 2015-12-24 IL IL243323A patent/IL243323A0/en unknown
-
2019
- 2019-05-07 JP JP2019087445A patent/JP2019167346A/ja active Pending
-
2021
- 2021-09-17 US US17/478,133 patent/US20220241432A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530233A5 (https=) | ||
| JP2019167346A5 (https=) | ||
| Araste et al. | Peptide-based targeted therapeutics: Focus on cancer treatment | |
| Barve et al. | Prostate cancer relevant antigens and enzymes for targeted drug delivery | |
| Natarajan et al. | Sustained-release from nanocarriers: a review | |
| WO2015154059A3 (en) | Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle | |
| JP2015516989A5 (https=) | ||
| WO2015123576A3 (en) | Targeted nanoparticle compositions and methods of their use to treat obesity | |
| WO2017044894A3 (en) | Cartilage-homing peptides | |
| IL275389B2 (en) | Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule | |
| BR212016030926U2 (pt) | conjugados de alvo e partículas e formulações dos mesmos | |
| BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| IL224048B (en) | Antiganic composition comprising whole killed or attenuated pathogenic eschrichia coli ( e.coli) cells for intradermal or subcutaneous administration for treating a human patient for crohn's disease | |
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| WO2016210376A3 (en) | Therapeutic peptides and methods of use thereof | |
| JP2017514800A5 (https=) | ||
| WO2016081835A3 (en) | Targeted structure-specific particulate delivery systems | |
| BR112014027905A2 (pt) | anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico. | |
| Weintraub et al. | Advances in intravesical therapy for the treatment of non‑muscle invasive bladder cancer | |
| WO2017062615A3 (en) | Combination therapy for the treatment of cancer | |
| JP2021529208A5 (https=) | ||
| Skalickova et al. | Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| JP2016515123A5 (https=) | ||
| JP2018509423A5 (https=) |